|
|
|
28.05.25 - 20:06
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 28.05.2025 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025
ISIN Name
BMG3728V1090 GAN LTD. DL-,01
BMG5753U1128 MAIDEN HLDGS LTD DL -,01
CA05455W1086 AWAKN LIFE SCIENCES CORP
CA0877372015 BETTER PLANT SCIENCES INC
NL0015001ZQ0 AFFIMED N.V. EO-,10...
|
|
|
21.05.25 - 12:45
|
Affimed: Wie das Kurswrack für einen Anlegerkreis zur +500%-Rakete wurde (Sharedeals)
|
|
|
Wenn Biotech-Aktien scheinbar am Boden liegen, wittern clevere Trader ihre Chance. Ein spektakulärer Trade bei Affimed zeigt, wie aus der Asche eines Insolvenzkandidaten ein echter Rendite-Kracher werden kann. Wenn es an der Börse einen Sektor gibt, in dem Hoffnung und Drama oft nur einen Wimpernschlag auseinanderliegen, dann ist es der Biotech-Bereich. Hier führen viele Wege […]
The post Affimed: Wie das Kurswrack für einen Anlegerkreis zur +500%-Rakete wurde first appeared on sharedeals.de....
|
|
|
14.05.25 - 12:48
|
Affimed Announces Receipt of Nasdaq Delisting Notice (GlobeNewswire EN)
|
|
|
MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market (“Nasdaq”)....
|
|
|
|
|
13.05.25 - 14:18
|
Affimed Announces Filing for the Opening of Insolvency Proceedings (GlobeNewswire EN)
|
|
|
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany....
|
|
|
|
|
23.04.25 - 16:09
|
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting (GlobeNewswire EN)
|
|
|
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations....
|
|
|
|
|
21.04.25 - 12:33
|
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire EN)
|
|
|
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”)....
|
|
|
|
|
03.03.25 - 12:33
|
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire EN)
|
|
|
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time....
|
|
|
24.02.25 - 18:24
|
XFRA : Diverse Instrumente: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CASTOR MARITIME INC. 1C1 MHY1146L2082 BAW/UFN
AFFIMED N.V. EO-,10 A28A NL0015001ZQ0 BAW/UFN
AETHLON MEDIC.NEW DL-,001 EJU0 US00808Y4061 BAW/UFN
AMERICAN R.H. NEW DL-,001 B0Y US02919L5057 BAW/UFN
ARCADIA BIOSC.NEW.DL-,001 17D US0390143032 BAW/UFN
ENERGY FOCUS INC. DL-0001 FI4A US29268T5083 BAW/UFN
KARTOON STUD. NEW DL-,001 4XV0 US37229T5092 BAW/UFN
HOUSTON AMERN ENE.DL-,001 8H6H US44183U2096 BAW/UFN
ZOOMCAR HLDGS NEW DL-,001 EO30 US45784G2003 BAW/UFN
MARIN SOFTWARE DL -,001 2MA US56804T3041 BAW/UFN
NOVA LIFESTYLE DL-,01 15N US66979P3001 BAW/UFN
PLUS THERAPEUTICS ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
